Arthrocart Biotech is a French startup that is pioneering innovative solutions to combat knee osteoarthritis. Their groundbreaking product, Collafit®, is a next-generation biological meniscal implant developed to address the destruction of the meniscus and severe knee arthritis. This unique implant, made from a bio-composite material, promotes cartilage regeneration and offers a biological and regenerative solution for patients. Unlike traditional prosthetic options, Collafit® allows for cartilage regeneration in cases of severe knee arthritis, making it an ideal choice for younger patients with good physical performance.

Arthrocart Biotech stands out as the only company in the world that has developed a biological regenerative solution for knee osteoarthritis. They are currently conducting pre-clinical animal studies and plan to launch a multicenter clinical trial across several European countries and hopefully the United States in 2025. With renowned European and US surgeons experienced in meniscal implants, this trial aims to measure the results over a two-year test period to obtain regulatory approvals before commercialization.

The patented Collafit® implant has the potential to significantly reduce the number of knee prostheses on the global market by at least 40%. This revolutionary technology will be available to surgeons in France and internationally. Stay informed about Arthrocart Biotech's clinical trials and medical publications to witness the future of knee arthritis treatment.

Supported by Bpi France, Arthrocart Biotech has received significant support and subsidies throughout its development journey. They are actively seeking new financial partners, including investors and donors, to help propel their research and development efforts and prepare for the commercial launch of Collafit®. To learn more about Arthrocart Biotech, their history, team, and partners, visit their website or get in touch with their team.